HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,600,424 | +152.3% | 251,320 | +138.2% | 0.07% | +169.2% |
| Q2 2023 | $3,805,565 | +1405.7% | 105,505 | +1494.2% | 0.03% | +1200.0% |
| Q1 2023 | $252,741 | -90.2% | 6,618 | -85.5% | 0.00% | -86.7% |
| Q4 2022 | $2,591,681 | – | 45,548 | +505988.9% | 0.02% | – |
| Q3 2022 | $0 | -100.0% | 9 | -100.0% | 0.00% | -100.0% |
| Q2 2022 | $8,904,000 | +429.4% | 202,355 | +379.7% | 0.05% | +285.7% |
| Q1 2022 | $1,682,000 | +167.4% | 42,180 | +169.8% | 0.01% | +133.3% |
| Q4 2021 | $629,000 | -79.2% | 15,631 | -78.9% | 0.01% | -84.2% |
| Q3 2021 | $3,019,000 | -47.1% | 74,219 | -40.9% | 0.04% | -40.6% |
| Q2 2021 | $5,705,000 | +62.9% | 125,642 | +49.5% | 0.06% | +42.2% |
| Q1 2021 | $3,503,000 | -47.0% | 84,028 | -45.7% | 0.04% | -50.5% |
| Q4 2020 | $6,610,000 | +332.0% | 154,772 | +165.8% | 0.09% | +295.7% |
| Q3 2020 | $1,530,000 | -56.2% | 58,226 | -55.3% | 0.02% | -61.7% |
| Q2 2020 | $3,495,000 | +200.5% | 130,372 | +101.8% | 0.06% | +93.5% |
| Q1 2020 | $1,163,000 | -74.7% | 64,620 | -75.1% | 0.03% | -63.1% |
| Q4 2019 | $4,602,000 | +1833.6% | 259,556 | +1588.6% | 0.08% | +1580.0% |
| Q3 2019 | $238,000 | -59.6% | 15,371 | -55.2% | 0.01% | -54.5% |
| Q2 2019 | $589,000 | +216.7% | 34,280 | +196.8% | 0.01% | +83.3% |
| Q1 2019 | $186,000 | -31.9% | 11,551 | -23.1% | 0.01% | -60.0% |
| Q3 2018 | $273,000 | -27.6% | 15,018 | -32.8% | 0.02% | -21.1% |
| Q2 2018 | $377,000 | +45.6% | 22,346 | +69.1% | 0.02% | +26.7% |
| Q1 2018 | $259,000 | -51.4% | 13,212 | -49.7% | 0.02% | -46.4% |
| Q4 2017 | $533,000 | +149.1% | 26,290 | +113.1% | 0.03% | +133.3% |
| Q3 2017 | $214,000 | -60.4% | 12,338 | -70.8% | 0.01% | -65.7% |
| Q2 2017 | $541,000 | +253.6% | 42,221 | +172.4% | 0.04% | +191.7% |
| Q4 2016 | $153,000 | -34.3% | 15,500 | -19.6% | 0.01% | -20.0% |
| Q3 2016 | $233,000 | -15.3% | 19,281 | -39.5% | 0.02% | -6.2% |
| Q2 2016 | $275,000 | -26.7% | 31,874 | +14.1% | 0.02% | -15.8% |
| Q3 2015 | $375,000 | +111.9% | 27,947 | +52.3% | 0.02% | +90.0% |
| Q4 2014 | $177,000 | – | 18,355 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |